PFE
ACCE-researchedOverview
ACCE thesis
Pfizer discovers, manufactures, and sells small-molecule drugs, biologics, and vaccines across oncology, infectious disease, and rare disease - with Paxlovid, Eliquis, and Ibrance as current revenue anchors. The company's manufacturing scale and global distribution infrastructure, built out aggressively during COVID, creates a fixed-cost base that competitors can't replicate overnight. The real story right now is the $43B Seagen acquisition closing in late 2023, which drops a deep oncology ADC pipeline directly into Pfizer's commercial engine - Padcev and Tukysa alone address markets where pricing power is exceptional. At a forward P/E of 8.2 against a gross margin of 74.8%, the market is pricing in LOE cliff damage from Eliquis and Paxlovid normalization as a permanent impairment rather than a cyclical reset. If even two or three of the Seagen-derived assets hit label expansions by 2026, the current multiple looks like a crowded-short setup unwinding in slow motion.
- highEarnings decline acceleratingEPS down 10.1% YoY and QoQ revenue -17.7%, signalling sharp sequential deterioration beyond headline annual growth of +5.4%.
- moderateWeak growth quality scoreACCE Growth sub-score of 28/100 reflects poor forward growth visibility despite modest 5.4% YoY revenue gain.
- moderateLow overall ACCE scoreComposite score 56/100 with Momentum at 40 suggests weak price trend; stock trades ~14% below model fair value of $28.50.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
Valuation
INVESTORSix independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORThe full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROFollow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| GILD | Gilead Sciences Inc. Common Stock | $186.1B | - | -20.7% | 1.10 | 2.1% | - | Compare |
| NVO | Novo Nordisk A/S Common Stock | $191.0B | 10.7 | 59.8% | 0.67 | 4.2% | - | Compare |
| NOVO-B.CO | Novo Nordisk B | $191.2B | 10.7 | 59.8% | 0.63 | 4.2% | - | Compare |
| BMY | Bristol-Myers Squibb Company Common Stock | $127.9B | 13.8 | 46.6% | 2.44 | 4.0% | - | Compare |
| AMGN | Amgen Inc. Common Stock | $208.5B | 24.0 | 91.5% | 6.31 | 2.6% | - | Compare |
| SAN.PA | Sanofi | $101.9B | 22.9 | 5.7% | 0.26 | 5.5% | - | Compare |
Sector report card
Where PFE ranks against its sector peers on each metric.
News and Record
Press releases mentioning this company
- Business Wire•Sep 15, 2026Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- GlobeNewswire•Sep 15, 2026Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
- GlobeNewswire•Sep 7, 2026Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.